Trials / Completed
CompletedNCT04502667
Efficacy of Vitamin D Treatment in Pediatric Patients Hospitalized by COVID-19
Efficacy of Vitamin D Treatment in Pediatric Patients Hospitalized by COVID-19: Open Controlled Clinical Trial
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- Coordinación de Investigación en Salud, Mexico · Other Government
- Sex
- All
- Age
- 1 Month – 17 Years
- Healthy volunteers
- Not accepted
Summary
Open controlled clinical trial. Hospitalized pediatric patients with COVID-19 will be included. Upon admission to hospital serum determination of vitamin D, interleukins, ferritin and Dimer D will be performed. Subsequently, randomization will be performed to identify which group the patient belongs. Adverse effects will be evaluated on a daily basis. Serum levels of interleukin (IL) -2, 6, 7,10, ferritin and dimer-D will be taken at the beginning of hospitalization and on the 7th day after admission. It will be recorded if the patient presents deterioration of the respiratory function that requires endotracheal intubation and / or admission to intensive care and / or if he dies, and at what time of hospitalization does this outcome occur. The study will culminate when the patient is discharged from hospitalization.
Detailed description
Hospitalized pediatric patients with COVID-19 will be included. The diagnosis of COVID-19 performed through RT-PCR. Upon admission to hospital, a serum determination of Vitamin D, interleukins, ferritin and dimer-D will be performed. Subsequently, randomization will be performed to identify which group the patient belongs to. In case of being in the vitamin D group, in children under 12 months they will be given 1000U and in children over 12 months they will be given 2000U every 24 hours orally. Adverse effects will be evaluated on a daily basis. Subsequently, serum levels of interleukin (IL) -2, 6, 7,10, ferritin and dimer-D will be taken on day 7 of admission. It will be recorded if the patient presents deterioration of the respiratory function that requires endotracheal intubation and / or admission to intensive care and / or if he dies, and at what time of hospitalization does this outcome occur. The study will culminate when the patient is discharged from hospitalization. On the day of hospital discharge, a blood sample will be taken to determine vitamin D.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cholecalciferol | 1000U or 2000U every 24 hours orally |
Timeline
- Start date
- 2020-07-15
- Primary completion
- 2021-03-31
- Completion
- 2021-09-15
- First posted
- 2020-08-06
- Last updated
- 2022-04-08
Locations
1 site across 1 country: Mexico
Source: ClinicalTrials.gov record NCT04502667. Inclusion in this directory is not an endorsement.